Loading…
Everest Organics (BSE 524790)₹254.95+2.39%Pharmaceuticals
Everest Organics is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 44.6 against a peer median of 22.1, and ROCE of 12.0% against a peer median of 12.1%, and latest-quarter sales growth of 19.2% against a peer median of 19.9%. By market cap it is #4 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Lyka Labs | 292 | — | −6.0 | −10.2 | 0.53 | 0.0 | 128 | −10 | 20.6 | — | vs BSE 524790 |
| Ambalal Sarabhai Enterprises | 276 | 20.6 | 12.1 | 12.3 | 0.36 | 0.0 | 202 | 18 | 7.9 | −51.5 | vs BSE 524790 |
| Astal Laboratories | 263 | 17.3 | 9.0 | 8.0 | 0.15 | 0.0 | 249 | 15 | — | — | vs BSE 524790 |
| Everest Organics | 255 | 44.6 | 12.0 | 7.6 | 0.66 | 0.0 | 196 | 6 | 19.2 | −9.7 | — |
| Sat Kartar Life | 245 | 14.2 | 36.0 | 26.5 | 0.04 | 0.5 | 201 | 17 | 26.7 | 28.4 | vs BSE 524790 |
| BDH Industries | 240 | 22.1 | 19.9 | 14.8 | 0.03 | 1.2 | 96 | 11 | 62.8 | 15.6 | vs BSE 524790 |
| Zenotech Laboratories | 238 | — | 4.6 | −1.2 | 0.00 | 0.0 | 44 | −1 | 10.2 | −145.0 | vs BSE 524790 |
| Accretion Nutraveda | 237 | 47.2 | 27.8 | 25.1 | 0.12 | 0.0 | 34 | 5 | 80.4 | 56.1 | vs BSE 524790 |
| Accretion Pharmaceuticals | 225 | 23.3 | 28.9 | 27.6 | 0.23 | 0.0 | 89 | 10 | 18.2 | 13.9 | vs BSE 524790 |
| Gennex Laboratories | 218 | 11.2 | 11.0 | 9.2 | 0.36 | 0.0 | 173 | 21 | 16.5 | −6.8 | vs BSE 524790 |
| Sanjivani Paranteral | 214 | 28.8 | 18.0 | 15.6 | 0.30 | 0.3 | 69 | 7 | 33.3 | 44.2 | vs BSE 524790 |
| Peer median | 240 | 22.1 | 12.1 | 12.3 | 0.23 | 0.0 | 128 | 10 | 19.9 | 13.9 |
Listed companies closest to Everest Organics in Pharmaceuticals include Lyka Labs, Ambalal Sarabhai Enterprises, Astal Laboratories, Sat Kartar Life, BDH Industries, Zenotech Laboratories, Accretion Nutraveda, Accretion Pharmaceuticals.
Lyka Labs, with a market cap of ₹292 Cr.
Everest Organics trades at a P/E of 44.6; the median of its peer set is 22.1. A P/E above or below the median is a description, not a judgement on value.
Everest Organics' return on capital employed is 12.0%, below the peer median of 12.1%.